The stock of NanoString Technologies Inc (NASDAQ:NSTG) is a huge mover today! About 82,666 shares traded hands. NanoString Technologies Inc (NASDAQ:NSTG) has risen 19.87% since March 7, 2016 and is uptrending. It has outperformed by 12.28% the S&P500.
The move comes after 9 months positive chart setup for the $438.44 million company. It was reported on Oct, 10 by Barchart.com. We have $58.24 PT which if reached, will make NASDAQ:NSTG worth $710.27 million more.
Analysts await NanoString Technologies Inc (NASDAQ:NSTG) to report earnings on November, 7. They expect $-0.51 EPS, down 4.08% or $0.02 from last year’s $-0.49 per share. After $-0.55 actual EPS reported by NanoString Technologies Inc for the previous quarter, Wall Street now forecasts -7.27% EPS growth.
According to Zacks Investment Research, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 2.52 in 2016 Q2. Its up 1.31, from 1.21 in 2016Q1. The ratio is positive, as 9 funds sold all NanoString Technologies Inc shares owned while 12 reduced positions. 15 funds bought stakes while 38 increased positions. They now own 16.55 million shares or 3.90% more from 15.93 million shares in 2016Q1.
Tfs Ltd accumulated 0.06% or 26,384 shares. Levin Strategies Lp last reported 0% of its portfolio in the stock. Pier Capital Limited Liability holds 202,405 shares or 0.46% of its portfolio. Bank Of America Corporation De holds 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG) for 3,610 shares. Strs Ohio, a Ohio-based fund reported 31,900 shares. Redmile Grp Inc Limited last reported 2.35% of its portfolio in the stock. Nicholas Inv Prtnrs Limited Partnership has 0.14% invested in the company for 160,472 shares. State Bank Of Montreal Can last reported 245 shares in the company. Blackrock, a Delaware-based fund reported 6,974 shares. Commercial Bank Of New York Mellon Corp has invested 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). The New York-based Bnp Paribas Arbitrage Sa has invested 0% in NanoString Technologies Inc (NASDAQ:NSTG). Rs Inv Co Limited Com reported 27,050 shares or 0% of all its holdings. Geode Cap Mgmt Ltd Com, a Massachusetts-based fund reported 88,618 shares. Da Davidson And last reported 1,000 shares in the company. Driehaus Mgmt Limited Liability has invested 0.08% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG).
Insider Transactions: Since August 12, 2016, the stock had 0 buys, and 6 sales for $8.52 million net activity. $669,812 worth of NanoString Technologies Inc (NASDAQ:NSTG) was sold by WAITE CHARLES P JR on Tuesday, August 23. Another trade for 3,961 shares valued at $65,357 was sold by BURNS WAYNE.
Another recent and important NanoString Technologies Inc (NASDAQ:NSTG) news was published by Quotes.Wsj.com which published an article titled: “News NanoString Technologies Inc.NSTG” on May 20, 2013.
NSTG Company Profile
NanoString Technologies, Inc., incorporated on June 20, 2003, develops, makes and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Firm operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Firm markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use. The Company’s molecular diagnostic product Prosigna Breast Cancer Assay, or Prosigna, provides an assessment of a patient’s risk of recurrence for breast cancer. The Firm has an installed base of over 350 systems, which its clients have used to publish more than 1,000 peer-reviewed papers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.